This HTML5 document contains 38 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n11http://linked.opendata.cz/resource/drugbank/drug/DB05288/identifier/chemspider/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/drugbank/drug/DB05288/identifier/wikipedia/
n6http://bio2rdf.org/drugbank:
n9http://linked.opendata.cz/resource/drugbank/drug/DB05288/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://linked.opendata.cz/resource/drugbank/drug/DB05288/identifier/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05288
rdf:type
n3:Drug
n3:description
Anecortave acetate (Retaane) is an analog of cortisol acetate; among the modifications to the steroid are the removal of the 11ß hydroxyl OH group and an addition of a 21-acetate group. As a result of these modifications, anecortave acetate lacks the typical antiinflammatory and immunosuppressive properties of glucocorticoids.Alcon Inc. is developing and marketing Retaane.
n3:generalReferences
# Augustin A: Anecortave acetate in the treatment of age-related macular degeneration. Clin Interv Aging. 2006;1(3):237-46. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18046876
n3:group
investigational
n3:indication
Investigated for use/treatment in glaucoma and macular degeneration.
owl:sameAs
n6:DB05288
dcterms:title
anecortave acetate
adms:identifier
n9:111332 n10:Anecortave n11:99892 n12:DB05288
n3:mechanismOfAction
Anecortave acetate functions as an antiangiogenic agent, inhibiting blood vessel growth by decreasing extracellular protease expression and inhibiting endothelial cell migration. Its angiostatic activity does not seem to be mediated through any of the commonly known pharmacological receptors. (Ophthalmology 2004;111:2316-7) RETAANE blocks signals from multiple growth factors because it acts downstream and independent of the initiating angiogenic stimuli and inhibits angiogenesis subsequent to the angiogenic stimulation.
n3:IUPAC-Name
n4:271B3FF1-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B3FF7-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B3FF6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B3FF3-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B3FF4-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B3FF5-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B3FEF-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B3FED-363D-11E5-9242-09173F13E4C5 n4:271B3FF0-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B3FEE-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B3FFD-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B3FFE-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B3FF8-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B3FF9-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B3FFB-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B3FFA-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B3FFC-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4003-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4005-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4006-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4002-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4001-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4004-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B3FF2-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B3FFF-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4000-363D-11E5-9242-09173F13E4C5